remdesivir - for COVID-19 severe or critically   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.10 [0.49, 2.45]< 10%1 study (1/-)40.8 %lownot evaluable highcrucial-
clinical improvement 1.23 [0.87, 1.74]> 10%1 study (1/-)87.7 %lownot evaluable highimportant-
clinical improvement (14-day) 1.21 [0.64, 2.28]> 10%1 study (1/-)71.9 %lownot evaluable highimportant-
clinical improvement (28-day) 1.37 [0.79, 2.39]> 10%1 study (1/-)86.8 %lownot evaluable highimportant-
clinical improvement (7-day) 0.99 [0.18, 5.51]> 10%1 study (1/-)49.4 %lownot evaluable highimportant-
clinical improvement (time to event analysis only) 1.23 [0.87, 1.74]> 10%1 study (1/-)87.7 %lownot evaluable highimportant-

-- safety endpoints 00

AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1/-)6.0 %lownot evaluable highimportant-
serious adverse events 0.64 [0.33, 1.23]< 10%1 study (1/-)91.0 %lownot evaluable highimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 91 91